This trial is investigating the safety and effectiveness of a personalised immunotherapy for patients with recurrent or untreatable malignant brain tumours. The trial is being conducted by the NeuroVita Clinic of Interventional and Restorative Neurology and Therapy in conjunction with Blokhin's Russian Cancer Research Center and proposes to enrol 60 patients by invitation only between December 2012 & and December 2017. The trial is comparing the use of a combination either of cytotoxic lymphocytes harvested from the patient's blood after administration of the dendritic vaccine with either donated blood stem cells (first experimental group), or the patient's own blood stem cells (second experimental group). Participants will be monitored for complications and assessed for changes in their clinical condition, including disappearance of tumour and greater than 50% reduction in tumour size.